PharmaCyte Biotech, Inc.PMCBNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | -177.36% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -152.69% | +0.00% | +772.28% | -135.69% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -164.74% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -164.74% | +0.00% |
| Weighted Average Shares Growth | -29.48% | -19.14% | -15.45% | -13.61% | -11.02% |
| Weighted Average Shares Diluted Growth | -12.87% | -19.14% | -18.61% | -13.61% | -11.02% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -30.15% | -38.58% | -7.91% | -35.74% | +1.59% |
| Book Value per Share Growth | +6.11% | +1.80% | +55.33% | -4.87% | -6.54% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +18.82% | -6.74% | +34.56% | -0.89% | +44.75% |
| SG&A Expenses Growth | -23.96% | -51.67% | -14.64% | -35.79% | +22.35% |